Article
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Molecular cancer therapeutics - 1 Oct 2012
Kim Sun Mi, Kwon Oh-Joon, Hong Yun Kyoung, Kim Joo Hang, Solca Flavio, Ha Sang-Jun, Soo Ross A, Christensen James G, Lee Ji Hyun, Cho Byoung Chul
Abstract excerpt
The secondary T790M mutation in epidermal growth factor receptor (EGFR) is the major mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). Although irreversible EGFR TKIs, such as afatinib or dacomitinib, have been introduced to overcome the acquired resistance, they showed a limited efficacy in NSCLC with T790M. Herein, we identified the novel de novo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.